Agios Pharmaceuticals’ mitapivat meets primary endpoint in Phase 3 thalassemia trial

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative therapies in cellular metabolism and pyruvate kinase (PK) activation, has announced promising results from its global ... Read More